Moscow, Russia – 6 June 2019 – – Sistema PJSFC (“Sistema” or the “Corporation”) (LSE: SSA, MOEX: AFKS), a publicly traded diversified Russian holding company, and the International Medical Cluster (IMC) Foundation have signed a partnership agreement that calls for the parties to cooperate on a project to establish a full-fledged, multidisciplinary biotechnology research and development laboratory at the International Medical Cluster in Skolkovo. The agreement was signed at the St. Petersburg International Economic Forum by Sistema Managing Partner Artem Sirazutdinov and IMC CEO Mikhail Yugai.

Sistema’s biotech lab will be used to conduct scientific research activities in the areas of genetic diagnostics, predictive medicine, drug development and integration of modern technologies into clinical practice.

The IMC Foundation commits to support Sistema as it becomes a resident of the IMC and will ensure that all necessary infrastructure is supplied for the establishment of the laboratory on the site. For its part, Sistema will invest funds in equipment and technical outfitting of the R&D lab, as well as retaining highly qualified professionals to implement the project.

Sistema Managing Partner Artem Sirazutdinov said: “The development of Russian healthcare and pharmacology are priority investment areas for Sistema. Early diagnosis of genetic diseases and ensuring that cell-based treatments become routine practice are just some of the challenges set before our R&D lab. We are delighted to be partnering with the IMC Foundation to deliver on this socially important project that will improve quality of life for our countrymen.” 

IMC CEO Mikhail Yugai: “The IMC's most important job is to create a conducive environment for the development of Russian healthcare. Attracting best international practice in medicine into Russia is not enough, because today medicine can exist and develop only on the basis of three areas: education, clinical research and experienced manufacturing. We are pleased that the establishment of this R&D lab is being undertaken by an organisation that dedicates particular attention to the development of Russian healthcare. Establishing a biotech lab to the highest international standards will provide for the resolution of timely tasks targeted on the development of personalised medicine and tools for early diagnosis of genetic diseases.”

***

For further information, please visit www.sistema.com or contact:

Search by industry

Search by alpha index

A B C D F G H I K L M N O P R S T U V W X Z